Tracking the evolution of resistance to ALK tyrosine kinase inhibitors through longitudinal analysis of circulating tumor DNA
I Dagogo-Jack, AR Brannon, LA Ferris… - JCO precision …, 2018 - ascopubs.org
Purpose ALK (anaplastic lymphoma kinase) rearrangements predict for sensitivity to ALK
tyrosine kinase inhibitors (TKIs); however, responses to ALK TKIs are generally short lived …
tyrosine kinase inhibitors (TKIs); however, responses to ALK TKIs are generally short lived …
Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity
I Dagogo-Jack, M Rooney, JJ Lin, RJ Nagy… - Clinical Cancer …, 2019 - AACR
Purpose: Acquired resistance to next-generation ALK tyrosine kinase inhibitors (TKIs) is
often driven by secondary ALK mutations. Here, we investigated utility of plasma genotyping …
often driven by secondary ALK mutations. Here, we investigated utility of plasma genotyping …
[HTML][HTML] Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients
Background Sequential treatment with different generations of anaplastic lymphoma kinase
(ALK) inhibitors have been widely applied to ALK-positive lung cancer; however, resistance …
(ALK) inhibitors have been widely applied to ALK-positive lung cancer; however, resistance …
Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer
E Pailler, V Faugeroux, M Oulhen, L Mezquita… - Clinical Cancer …, 2019 - AACR
Purpose: Patients with anaplastic lymphoma kinase (ALK)–rearranged non–small-cell lung
cancer (NSCLC) inevitably develop resistance to ALK inhibitors. New diagnostic strategies …
cancer (NSCLC) inevitably develop resistance to ALK inhibitors. New diagnostic strategies …
[HTML][HTML] Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer
Introduction Despite initial effectiveness of ALK receptor tyrosine kinase inhibitors (TKIs) in
patients with ALK+ NSCLC, therapeutic resistance will ultimately develop. Serial tracking of …
patients with ALK+ NSCLC, therapeutic resistance will ultimately develop. Serial tracking of …
Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors
M Kwon, BM Ku, S Olsen, S Park, M Lefterova… - Cancer …, 2022 - Wiley Online Library
Background Patients with ALK‐rearranged non‐small cell lung cancer (ALK+ NSCLC)
inevitably acquire resistance to ALK inhibitors. Longitudinal monitoring of cell‐free plasma …
inevitably acquire resistance to ALK inhibitors. Longitudinal monitoring of cell‐free plasma …
Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
CE McCoach, CM Blakely, KC Banks, B Levy… - Clinical Cancer …, 2018 - AACR
Purpose: Patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor
anaplastic lymphoma kinase (ALK) gene fusions benefit from treatment with ALK inhibitors …
anaplastic lymphoma kinase (ALK) gene fusions benefit from treatment with ALK inhibitors …
Targeting ALK: precision medicine takes on drug resistance
JJ Lin, GJ Riely, AT Shaw - Cancer discovery, 2017 - AACR
Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-
rearranged malignancies, including non–small cell lung cancer. However, the clinical …
rearranged malignancies, including non–small cell lung cancer. However, the clinical …
Detection of ALK and KRAS mutations in circulating tumor DNA of patients with advanced ALK-positive NSCLC with disease progression during crizotinib treatment
P Bordi, M Tiseo, E Rofi, I Petrini, G Restante… - Clinical lung cancer, 2017 - Elsevier
Background In patients with anaplastic lymphoma kinase (ALK)-positive non–small-cell lung
cancer (NSCLC), disease progression occurs after a median of 9 to 10 months of crizotinib …
cancer (NSCLC), disease progression occurs after a median of 9 to 10 months of crizotinib …
Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis
AK Angeles, P Christopoulos, Z Yuan, S Bauer… - NPJ Precision …, 2021 - nature.com
Targeted kinase inhibitors improve the prognosis of lung cancer patients with ALK
alterations (ALK+). However, due to the emergence of acquired resistance and varied …
alterations (ALK+). However, due to the emergence of acquired resistance and varied …
相关搜索
- evolution of resistance tumor dna
- evolution of resistance kinase inhibitors
- kinase inhibitors tumor dna
- evolution of resistance longitudinal analysis
- longitudinal analysis tumor dna
- kinase inhibitors longitudinal analysis
- dna for the detection inhibitor resistance
- clinical utility inhibitor resistance
- alk fusions inhibitor resistance
- disease progression tumor dna
- lung cancer tumor dna
- alk fusions dna for the detection
- alk inhibitors mutation diversity
- crizotinib treatment tumor dna
- kras mutations tumor dna
- therapeutic response tumor dna